This article is more than 5 years old. Information may no longer be current.
MMC effective in treating primary or recurrent conjunctival-corneal intraepithelial neoplasia
Ophthal Plast Reconstr Surg. 2009;25(4):296-299.
Click Here to Manage Email Alerts
Topical mitomycin C 0.02% was effective in both reducing recurrence rate and treating primary and recurrent conjunctival-corneal intraepithelial neoplasia, a long-term study found.
The prospective, nonrandomized, noncontrolled study looked at 23 patients with primary or recurrent conjunctival-corneal intraepithelial neoplasia. Patients were divided into two groups: Group one had 18 patients with primary conjunctival-corneal intraepithelial neoplasia, and group two had five patients with recurrent conjunctival-corneal intraepithelial neoplasia.
Both groups received topical MMC 0.02% four times a day over 28 consecutive days. Group one had a mean follow-up of 46 months, and group two had a mean follow-up of 54 months.
The researchers found that all patients had complete resolution of the lesion at 1 month. At 24 months after treatment, one patient (4.3%) had lesion recurrence.
"The use of topical MMC 0.02% for 28 consecutive days to treat primary or recurrent [conjunctival-corneal intraepithelial neoplasia] was effective and showed a low recurrence rate," the study authors said. "Corneal erosion occurred in 17.4% of cases and can occur as late as 24 months after treatment."
Corneal erosion developed in two patients with primary conjunctival-corneal intraepithelial neoplasia and two patients with recurrent lesions. According to the study, all cases of corneal erosion were treated successfully and occurred between 4 months and 24 months following treatment.